MX9603431A - Peptidos reconocidos por linfocitos citotoxicos, especificos al melanoma, y los usos para los mismos. - Google Patents

Peptidos reconocidos por linfocitos citotoxicos, especificos al melanoma, y los usos para los mismos.

Info

Publication number
MX9603431A
MX9603431A MX9603431A MX9603431A MX9603431A MX 9603431 A MX9603431 A MX 9603431A MX 9603431 A MX9603431 A MX 9603431A MX 9603431 A MX9603431 A MX 9603431A MX 9603431 A MX9603431 A MX 9603431A
Authority
MX
Mexico
Prior art keywords
melanoma
peptides
specific cytotoxic
cytotoxic lymphocytes
uses therefor
Prior art date
Application number
MX9603431A
Other languages
English (en)
Inventor
Craig L Slingluff
Victor H Engelhard
Donald F Hunt
Jeffrey Shabanowitz
Andrea L Cox
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26892817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9603431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Virginia filed Critical Univ Virginia
Publication of MX9603431A publication Critical patent/MX9603431A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
    • C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
    • C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se ha identificado epítopes de CTL específicos para melanoma por medio de mejoras en la técnica de identificacion de péptidos de reconstitucion de epítope, disociados de moléculas MHC de clase I sobre la superficie de las células tumorales. Los homologos de péptidos con un segmento del antígeno pMel-17 de melanoma-melanocito han demostrado ser estimuladores sumamente potentes de HLA-A2+CTL en diversas líneas de células CTL. Estos péptidos y los péptidos de la misma clase pueden ser usados para estimular las CTL para usarlas en inmunoterapia adoptiva o se pueden incorporar en conjugados inmunogénicos para uso como vacunas.
MX9603431A 1994-02-16 1995-02-16 Peptidos reconocidos por linfocitos citotoxicos, especificos al melanoma, y los usos para los mismos. MX9603431A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19739994A 1994-02-16 1994-02-16
US08/234,784 US6660276B1 (en) 1994-02-16 1994-04-29 Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
PCT/US1995/001991 WO1995022561A2 (en) 1994-02-16 1995-02-16 Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor

Publications (1)

Publication Number Publication Date
MX9603431A true MX9603431A (es) 1997-03-29

Family

ID=26892817

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9603431A MX9603431A (es) 1994-02-16 1995-02-16 Peptidos reconocidos por linfocitos citotoxicos, especificos al melanoma, y los usos para los mismos.

Country Status (9)

Country Link
US (1) US6660276B1 (es)
EP (1) EP0745095A1 (es)
AU (1) AU701531B2 (es)
CA (1) CA2182889C (es)
FI (1) FI963196A (es)
MX (1) MX9603431A (es)
NO (1) NO963344L (es)
NZ (1) NZ282183A (es)
WO (1) WO1995022561A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435292D1 (de) * 1993-03-05 2010-06-17 Epimmune Inc Verfahren zur herstellung von immunogenen hla-a2.1-bindenden peptiden
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
CA2188432C (en) * 1994-04-22 2011-02-01 Yutaka Kawakami Melanoma antigens
JP3556228B2 (ja) 1994-07-25 2004-08-18 ロシュ ダイアグノスティックス ゲーエムベーハー 複数の抗原を使用した特異的免疫グロブリンの測定
US5843648A (en) * 1995-01-10 1998-12-01 The United States Of America As Represented By The Secretary, Department Of Health And Human Services P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
US7501501B2 (en) 1995-09-26 2009-03-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services MHC-Class II restricted melanoma antigens and their use in therapeutic methods
EP0879282B1 (en) * 1996-01-17 2003-07-02 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
RS50101B (sr) * 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
AU712820B2 (en) * 1996-03-19 1999-11-18 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytotoxic lymphocytes, and uses therefor
US7019112B1 (en) 1996-03-19 2006-03-28 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
CA2522812C (en) 2003-04-18 2012-08-21 Idm Pharma, Inc. Hla-a2 tumor associated antigen peptides and compositions
AU2004249254B2 (en) * 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
WO2006037059A2 (en) 2004-09-27 2006-04-06 The Johns Hopkins Universtiy Point-of-care mass spectrometer system
WO2006138567A2 (en) 2005-06-17 2006-12-28 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
WO2007103009A2 (en) * 2006-03-01 2007-09-13 Janssen Pharmaceutica N.V. CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES
CN116987174A (zh) * 2023-07-26 2023-11-03 百蓁生物技术(武汉)有限公司 一种pHLA复合物裂解液及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000991A1 (en) 1984-07-24 1986-02-13 Commonwealth Serum Laboratories Commission Method for determining mimotopes
WO1986006487A1 (en) 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
WO1994023067A1 (en) 1993-03-31 1994-10-13 Abbott Laboratories Tumor-associated antigens recognized by t cells and the uses of these antigens
US5610031A (en) * 1993-10-27 1997-03-11 The General Hospital Corporation B1k chain of laminin and methods of use
US5472856A (en) * 1993-12-21 1995-12-05 Immunobiology Research Institute, Inc. Recombinant human thymopoietin proteins and uses therefor
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods

Also Published As

Publication number Publication date
WO1995022561A2 (en) 1995-08-24
FI963196A0 (fi) 1996-08-15
US6660276B1 (en) 2003-12-09
AU1921595A (en) 1995-09-04
FI963196A (fi) 1996-10-15
EP0745095A1 (en) 1996-12-04
AU701531B2 (en) 1999-01-28
CA2182889C (en) 2008-12-23
NO963344L (no) 1996-10-14
WO1995022561A3 (en) 1996-03-07
NZ282183A (en) 1998-07-28
NO963344D0 (no) 1996-08-09
CA2182889A1 (en) 1995-08-24

Similar Documents

Publication Publication Date Title
MX9603431A (es) Peptidos reconocidos por linfocitos citotoxicos, especificos al melanoma, y los usos para los mismos.
TR200100936T2 (tr) Terapötik aşılama
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
WO1997035021A3 (en) Prostate specific antigen oligo-epitope peptide
AU6597998A (en) HLA-A2.1 binding peptides and their uses
AU7392296A (en) Dendritic cell stimulatory factor
ZA952375B (en) Isolated tumor rejection antigen precursor mage-2 derived peptides and uses thereof
IL134043A0 (en) Cellular vesicle called "exosome", its preparation and use thereof in immune stimulation
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
AU5898400A (en) Hla binding peptides and their uses
CA2267157A1 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
NZ335749A (en) Formulation in the form of a patch for transcutaneous immunization comprising an antigen and an adjuvant
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
DK1123086T3 (da) Kunstige antigen-specifikke celler og tilhørende fremgangsmåder
WO1999004265A3 (en) Cancer associated nucleic acids and polypeptides
DE69733352D1 (de) Hla-a2.1 bindende peptide und deren verwendung
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
EP0531401A4 (en) Enhancing the association of exogenous peptides with class i mhc molecules on immune system cells
DE69529515D1 (de) Die regulation der aktivität zytotoxischer t-zelllymphozyten mit peptiden der mhc-klasse i
AU5423898A (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
CA2249390A1 (en) Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor
WO2000012122A3 (de) Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
AU2883597A (en) Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
PT996636E (pt) Antigenio ha-1
HK1076476A1 (en) Ptprk immunogenic peptide